Travere Therapeutics rated a Buy after Filspari’s FDA approval for FSGS—only therapy available. Read TVTX's valuation upside, ...
AZN's Ultomiris hits key goal in IgAN study, showing early proteinuria reduction as it eyes accelerated approval in major ...
Italian drive to increase diagnosis rates in children with severe genetic disorders is achieving transformative results. The ...
Already approved to treat four rare diseases, AstraZeneca’s Ultomiris has shown its ability against another rare disorder, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results